Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Empagliflozin (BI 10773)
DRUG
2 trials
Sponsors
Boehringer Ingelheim
, Fundación para la Investigación del Hospital Clínico de Valencia
Conditions
Diabetes Mellitus Type 2
Healthy
Phase 1
Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid
Completed
NCT01634100
Boehringer Ingelheim
Healthy
Start: 2012-06-30
End: 2012-08-31
Updated: 2014-07-03
Phase 4
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Active, not recruiting
NCT06851962
Fundación para la Investigación del Hospital Clínico de Valencia
Diabetes Mellitus Type 2
Start: 2025-05-26
End: 2026-06-30
Target: 504
Updated: 2026-02-23
Related Papers
Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.
2014-02-01
26 citations